OncoMatch/Clinical Trials/NCT05998642
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Is NCT05998642 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Methotrexate and Rituximab (where available) for non-hodgkin lymphoma.
Treatment: Methotrexate · Rituximab (where available) · Ibrutinib — This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
No prior radiation therapy for PCNSL is allowed
Lab requirements
Blood counts
Absolute neutrophils ≥ 1.0 x 10^9/L (independent of growth factor support); Platelets ≥ 75 x 10^9/L
Kidney function
Creatinine clearance ≥ 50 mL/min
Liver function
Bilirubin ≤ 1.5 x UNL; ALT ≤ 3.0 x UNL (if AST >3 x UNL consult with CTG re: eligibility)
Cardiac function
No clinically significant cardiac disease (see exclusion criteria); LVEF ≥ 50% required for patients with distant clinically significant cardiac history
Patients must have adequate organ and marrow function measured within 7 days prior to enrollment including: Absolute neutrophils ≥ 1.0 x 10^9/L (independent of growth factor support); Platelets ≥ 75 x 10^9/L; Bilirubin ≤ 1.5 x UNL; ALT ≤ 3.0 x UNL (if AST >3 x UNL consult with CTG re: eligibility); Creatinine clearance ≥ 50 mL/min. Patients with clinically significant cardiac disease, including: angina pectoris, symptomatic pericarditis, coronary artery bypass grafting, coronary angioplasty, or stenting, or myocardial infarction in the previous 12 months; history of documented congestive heart failure (NYHA III-IV) or cardiomyopathy; uncontrolled hypertension; atrial or ventricular arrhythmias (controlled atrial fibrillation eligible). LVEF ≥ 50% required for patients with distant clinically significant cardiac history.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify